3,4-methylenedioxyamphetamine has been researched along with sorafenib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, N; Lan, H; Li, H; Yi, C; Zhang, M; Zhao, F | 1 |
1 other study(ies) available for 3,4-methylenedioxyamphetamine and sorafenib
| Article | Year |
|---|---|
TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.
Topics: 3,4-Methylenedioxyamphetamine; Carcinoma, Hepatocellular; Ferroptosis; Humans; Liver Neoplasms; Reactive Oxygen Species; Sorafenib; TEA Domain Transcription Factors | 2023 |